_id

690f3745ccc777a4e85d17ce

Ticker

BNR

Name

Burning Rock Biotech Ltd

Exchange

NASDAQ

Address

No. 5, Xingdao Ring Road North, Guangzhou, China, 510005

Country

USA

Sector

Healthcare

Industry

Diagnostics & Research

Currency

USD

Website

https://www.brbiotech.com

Description

Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People's Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its key products include OncoScreen Focus, a multi-gene tumor mutation co-detection test kit for non-small cell lung cancer (NSCLC) patients; OncoScreen Plus, a pan-cancer test for tissue samples; OncoCompass Plus, a corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; and ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers. The company also provides CanCatch, a pre-operative ctDNA detection and post-operative minimal residual disease calling for relapsed patients; OncoMaster, an automatic NGS data analysis and report interpretation machine; as well as Magnis BR-customized version of its key products. In addition, it engages in the facilitation of laboratory equipment sales and sales of reagent kits. The company has a development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA. Burning Rock Biotech Limited was founded in 2014 and is headquartered in Guangzhou, the People's Republic of China.

Last Close

17.05

Volume

63822

Current Price

15.75

Change

-7.624633431085048

Last Updated

2025-11-28T13:03:07.264Z

Image

data:image/webp;base64,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

Ipo Date

2020-06-12T00:00:00.000Z

Market Cap

229759168

Next Dividend Date

-

Dividend Frequency

-

Dividend Rate

-

Dividend Yield

0

Sentiment

0.7108

Sentiment Sources

5

Rating

5

Target Price

4.03

Strong Buy

1

Buy

0

Hold

0

Sell

0

Strong Sell

0

Current Quarter

2025-09-30

Revenue

131616999

Cost Of Revenue

32773000

Gross Profit

98844000

Operating Expenses

114974999

Operating Income

-16131000

Interest Expense

15000

Pretax Income

-16546000

Net Income

-16758000

Eps

-15.56237393529886

Dividends Per Share

-

Shares Outstanding

9034111

Income Tax Expense

212000

EBITDA

-3284250

Operating Margin

-12.25601565341875

Total Other Income Expense Net

-415000

Cash

463994000

Short Term Investments

-

Receivables

196890000

Inventories

54469000

Total Current Assets

739323000

Property Plant Equipment

66036000

Total Assets

812168000

Payables

34277000

Short Term Debt

16803000

Long Term Debt

1800000

Total Liabilities

262591000

Equity

549577000

Depreciation

12846750

Change In Working Capital

-

Cash From Operations

16393999

Capital Expenditures

0

Cash From Investing

-2747000

Cash From Financing

-

Net Change In Cash

11955000

PE

-

PB

0.030860172459910074

ROE

-3.049254244628141

ROA

-2.063366200096532

FCF

16393999

Fcf Percent

0.12455837106573141

Piotroski FScore

2

Health Score

45

Deep Value Investing Score

8.5

Defensive Investing Score

7

Dividend Investing Score

3

Economic Moat Investing Score

5.8

Garp Investing Score

4

Growth Investing Score

2.5

Momentum Investing Score

6

Net Net Investing Score

8

Quality Investing Score

4.5

Value Investing Score

5.5

Quarters > 0 > quarter

2025-09-30

Quarters > 0 > income Statement > revenue

131616999

Quarters > 0 > income Statement > cost Of Revenue

32773000

Quarters > 0 > income Statement > gross Profit

98844000

Quarters > 0 > income Statement > operating Expenses

114974999

Quarters > 0 > income Statement > operating Income

-16131000

Quarters > 0 > income Statement > interest Expense

15000

Quarters > 0 > income Statement > pretax Income

-16546000

Quarters > 0 > income Statement > net Income

-16758000

Quarters > 0 > income Statement > eps

-15.56237393529886

Quarters > 0 > income Statement > dividends Per Share

-

Quarters > 0 > income Statement > shares Outstanding

1076828

Quarters > 0 > income Statement > income Tax Expense

212000

Quarters > 0 > income Statement > EBITDA

-3284250

Quarters > 0 > income Statement > operating Margin

-12.25601565341875

Quarters > 0 > income Statement > total Other Income Expense Net

-415000

Quarters > 0 > balance Sheet > cash

463994000

Quarters > 0 > balance Sheet > short Term Investments

-

Quarters > 0 > balance Sheet > receivables

196890000

Quarters > 0 > balance Sheet > inventories

54469000

Quarters > 0 > balance Sheet > total Current Assets

739323000

Quarters > 0 > balance Sheet > property Plant Equipment

66036000

Quarters > 0 > balance Sheet > total Assets

812168000

Quarters > 0 > balance Sheet > payables

34277000

Quarters > 0 > balance Sheet > short Term Debt

16803000

Quarters > 0 > balance Sheet > long Term Debt

1800000

Quarters > 0 > balance Sheet > total Liabilities

262591000

Quarters > 0 > balance Sheet > equity

549577000

Quarters > 0 > cash Flow > net Income

-16758000

Quarters > 0 > cash Flow > depreciation

12846750

Quarters > 0 > cash Flow > change In Working Capital

-

Quarters > 0 > cash Flow > cash From Operations

16393999

Quarters > 0 > cash Flow > capital Expenditures

0

Quarters > 0 > cash Flow > cash From Investing

-2747000

Quarters > 0 > cash Flow > cash From Financing

-

Quarters > 0 > cash Flow > net Change In Cash

11955000

Quarters > 0 > ratios > PE

-15.56237393529886

Quarters > 0 > ratios > PB

0.030860172459910074

Quarters > 0 > ratios > ROE

-3.049254244628141

Quarters > 0 > ratios > ROA

-2.063366200096532

Quarters > 0 > ratios > FCF

16393999

Quarters > 0 > ratios > Piotroski FScore

2

Quarters > 0 > ratios > fcf Percent

0.12455837106573141

Quarters > 0 > health Score

45

Quarters > 1 > quarter

2025-06-30

Quarters > 1 > income Statement > revenue

148554000

Quarters > 1 > income Statement > cost Of Revenue

40451000

Quarters > 1 > income Statement > gross Profit

108103000

Quarters > 1 > income Statement > operating Expenses

119600000

Quarters > 1 > income Statement > operating Income

-11497000

Quarters > 1 > income Statement > interest Expense

-

Quarters > 1 > income Statement > pretax Income

-9458000

Quarters > 1 > income Statement > net Income

-9702000

Quarters > 1 > income Statement > eps

-9.009795436225655

Quarters > 1 > income Statement > dividends Per Share

-

Quarters > 1 > income Statement > shares Outstanding

1076828

Quarters > 1 > income Statement > income Tax Expense

244000

Quarters > 1 > income Statement > EBITDA

1349750

Quarters > 1 > income Statement > operating Margin

-7.73927326090176

Quarters > 1 > income Statement > total Other Income Expense Net

2039000

Quarters > 1 > balance Sheet > cash

452721000

Quarters > 1 > balance Sheet > short Term Investments

-

Quarters > 1 > balance Sheet > receivables

204724000

Quarters > 1 > balance Sheet > inventories

57810000

Quarters > 1 > balance Sheet > total Current Assets

740812000

Quarters > 1 > balance Sheet > property Plant Equipment

77136000

Quarters > 1 > balance Sheet > total Assets

824931000

Quarters > 1 > balance Sheet > payables

32164000

Quarters > 1 > balance Sheet > short Term Debt

19455000

Quarters > 1 > balance Sheet > long Term Debt

1800000

Quarters > 1 > balance Sheet > total Liabilities

260696000

Quarters > 1 > balance Sheet > equity

564235000

Quarters > 1 > cash Flow > net Income

-9702000

Quarters > 1 > cash Flow > depreciation

12846750

Quarters > 1 > cash Flow > change In Working Capital

-

Quarters > 1 > cash Flow > cash From Operations

-44349000

Quarters > 1 > cash Flow > capital Expenditures

0

Quarters > 1 > cash Flow > cash From Investing

207000

Quarters > 1 > cash Flow > cash From Financing

2000000

Quarters > 1 > cash Flow > net Change In Cash

-42382000

Quarters > 1 > ratios > PE

-9.009795436225655

Quarters > 1 > ratios > PB

0.030058470318218473

Quarters > 1 > ratios > ROE

-1.7194963091619626

Quarters > 1 > ratios > ROA

-1.176098364590493

Quarters > 1 > ratios > FCF

-44349000

Quarters > 1 > ratios > Piotroski FScore

0

Quarters > 1 > ratios > fcf Percent

-0.2985379054081344

Quarters > 1 > health Score

33

Quarters > 2 > quarter

2025-03-31

Quarters > 2 > income Statement > revenue

133082000

Quarters > 2 > income Statement > cost Of Revenue

35681000

Quarters > 2 > income Statement > gross Profit

97401000

Quarters > 2 > income Statement > operating Expenses

112580000

Quarters > 2 > income Statement > operating Income

-15179000

Quarters > 2 > income Statement > interest Expense

-

Quarters > 2 > income Statement > pretax Income

-13276000

Quarters > 2 > income Statement > net Income

-13500000

Quarters > 2 > income Statement > eps

-12.544544749178797

Quarters > 2 > income Statement > dividends Per Share

-

Quarters > 2 > income Statement > shares Outstanding

1076165

Quarters > 2 > income Statement > income Tax Expense

224000

Quarters > 2 > income Statement > EBITDA

-15179000

Quarters > 2 > income Statement > operating Margin

-11.40574983844547

Quarters > 2 > income Statement > total Other Income Expense Net

1903000

Quarters > 2 > balance Sheet > cash

495145000

Quarters > 2 > balance Sheet > short Term Investments

6136000

Quarters > 2 > balance Sheet > receivables

176641000

Quarters > 2 > balance Sheet > inventories

65424000

Quarters > 2 > balance Sheet > total Current Assets

761543000

Quarters > 2 > balance Sheet > property Plant Equipment

84966000

Quarters > 2 > balance Sheet > total Assets

854717000

Quarters > 2 > balance Sheet > payables

35938000

Quarters > 2 > balance Sheet > short Term Debt

22524000

Quarters > 2 > balance Sheet > long Term Debt

-

Quarters > 2 > balance Sheet > total Liabilities

282915000

Quarters > 2 > balance Sheet > equity

571802000

Quarters > 2 > cash Flow > net Income

-13500000

Quarters > 2 > cash Flow > depreciation

52200000

Quarters > 2 > cash Flow > change In Working Capital

-41921000

Quarters > 2 > cash Flow > cash From Operations

-23527000

Quarters > 2 > cash Flow > capital Expenditures

5419000

Quarters > 2 > cash Flow > cash From Investing

-1531000

Quarters > 2 > cash Flow > cash From Financing

-74000

Quarters > 2 > cash Flow > net Change In Cash

-24756000

Quarters > 2 > ratios > PE

-12.544544749178797

Quarters > 2 > ratios > PB

0.029642426486790878

Quarters > 2 > ratios > ROE

-2.3609571145256574

Quarters > 2 > ratios > ROA

-1.5794701638086057

Quarters > 2 > ratios > FCF

-28946000

Quarters > 2 > ratios > Piotroski FScore

0

Quarters > 2 > ratios > fcf Percent

-0.21750499691919267

Quarters > 2 > health Score

33

Quarters > 3 > quarter

2024-12-31

Quarters > 3 > income Statement > revenue

126022000

Quarters > 3 > income Statement > cost Of Revenue

36600000

Quarters > 3 > income Statement > gross Profit

89422000

Quarters > 3 > income Statement > operating Expenses

172822000

Quarters > 3 > income Statement > operating Income

-46800000

Quarters > 3 > income Statement > interest Expense

-

Quarters > 3 > income Statement > pretax Income

-75980000

Quarters > 3 > income Statement > net Income

-81294000

Quarters > 3 > income Statement > eps

-0.7554223605409004

Quarters > 3 > income Statement > dividends Per Share

-

Quarters > 3 > income Statement > shares Outstanding

107613971

Quarters > 3 > income Statement > income Tax Expense

-

Quarters > 3 > income Statement > EBITDA

-

Quarters > 3 > income Statement > operating Margin

-37.13637301423561

Quarters > 3 > income Statement > total Other Income Expense Net

-30994000

Quarters > 3 > balance Sheet > cash

519849000

Quarters > 3 > balance Sheet > short Term Investments

-

Quarters > 3 > balance Sheet > receivables

152013000

Quarters > 3 > balance Sheet > inventories

53763000

Quarters > 3 > balance Sheet > total Current Assets

776618000

Quarters > 3 > balance Sheet > property Plant Equipment

100340000

Quarters > 3 > balance Sheet > total Assets

885305000

Quarters > 3 > balance Sheet > payables

33747000

Quarters > 3 > balance Sheet > short Term Debt

-

Quarters > 3 > balance Sheet > long Term Debt

-

Quarters > 3 > balance Sheet > total Liabilities

304478000

Quarters > 3 > balance Sheet > equity

580827000

Quarters > 3 > cash Flow > net Income

-81294000

Quarters > 3 > cash Flow > depreciation

-

Quarters > 3 > cash Flow > change In Working Capital

-

Quarters > 3 > cash Flow > cash From Operations

19062000

Quarters > 3 > cash Flow > capital Expenditures

0

Quarters > 3 > cash Flow > cash From Investing

-

Quarters > 3 > cash Flow > cash From Financing

-

Quarters > 3 > cash Flow > net Change In Cash

23915000

Quarters > 3 > ratios > PE

-0.7554223605409004

Quarters > 3 > ratios > PB

2.918115106993993

Quarters > 3 > ratios > ROE

-13.99625017432041

Quarters > 3 > ratios > ROA

-9.182598087664703

Quarters > 3 > ratios > FCF

19062000

Quarters > 3 > ratios > Piotroski FScore

2

Quarters > 3 > ratios > fcf Percent

0.15125930393105966

Quarters > 3 > health Score

45

Valuation > metrics > PE

-15.56237393529886

Valuation > metrics > PB

0.030860172459910074

Valuation > final Score

70

Valuation > verdict

96.9% Undervalued

Profitability > metrics > ROE

-3.049254244628141

Profitability > metrics > ROA

-2.2666682897732113

Profitability > metrics > Net Margin

-0.12732397887297217

Profitability > final Score

0

Profitability > verdict

Weak

Risk > metrics > Debt Equity

0.47780565780591255

Risk > metrics > Interest Coverage

-1075.4

Risk > final Score

-4242

Risk > verdict

High

Liquidity > metrics > Current Ratio

14.473825371965544

Liquidity > metrics > Quick Ratio

13.407478465152701

Liquidity > final Score

100

Liquidity > verdict

Great

Prev Valuations > 0

70

Prev Valuations > 1

70

Prev Valuations > 2

80

Prev Profitabilities > 0

0

Prev Profitabilities > 1

0

Prev Profitabilities > 2

0

Prev Risks > 0

56

Prev Risks > 1

28

Prev Risks > 2

42

Prev Liquidities > 0

100

Prev Liquidities > 1

100

Prev Liquidities > 2

100

Updated At

2025-12-14T00:17:30.416Z